pk-sim
There are 188 repositories under pk-sim topic.
Open-Systems-Pharmacology/PK-Sim
PK-Sim® is a comprehensive software tool for whole-body physiologically based pharmacokinetic modeling
Open-Systems-Pharmacology/Pregnancy-Models
Physiologically Based Pharmacokinetic Models for Pregnant Women
Open-Systems-Pharmacology/Digoxin-Model
Whole-body PBPK model of digoxin as P-gp DDI victim drug
Open-Systems-Pharmacology/Vancomycin-Model
Whole-body PBPK model of Vancomycin
Open-Systems-Pharmacology/Voriconazole-Model
Whole-body PBPK model of voriconazole as CYP2C19 substrate and CYP3A4 perpetrator drug
Open-Systems-Pharmacology/BOSTON-2018-Workshop
PK-Sim® & MoBi® workshop on integrating PBPK with QSP
Open-Systems-Pharmacology/Carbamazepine-Alprazolam-DDI
Modeling of published clinical Carbamazepine-Alprazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Carbamazepine-Efavirenz-DDI
Modeling of published clinical Carbamazepine-Efavirenz DDI studies for model evaluation
Open-Systems-Pharmacology/Carbamazepine-Midazolam-DDI
Modeling of published clinical Carbamazepine-Midazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Alfentanil-DDI
Modeling of published clinical Cimetidine-Alfentanil-DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Alprazolam-DDI
Modeling of published clinical Cimetidine-Alprazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Carbamazepine-DDI
Modeling of published clinical Cimetidine-Carbamazepine DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Midazolam-DDI
Modeling of published clinical Cimetidine-Midazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Model
Whole-body PBPK model of cimetidine (OCT2/MATE and CYP3A4 DDI perpetrator drug)
Open-Systems-Pharmacology/Cimetidine-Triazolam-DDI
Modeling of published clinical Cimetidine-Triazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Cimetidine-Verapamil-DDI
Modeling of published clinical Cimetidine-Verapamil-DDI studies for model evaluation
Open-Systems-Pharmacology/Clarithromycin-Midazolam-DDI
Modeling of published clinical Clarithromycin-Midazolam-DDI studies for model evaluation
Open-Systems-Pharmacology/Efavirenz-Model
Whole-body PBPK model of efavirenz as CYP3A4 perpetrator drug
Open-Systems-Pharmacology/Erythromycin-Carbamazepine-DDI
Modeling of published clinical Erythromycin-Carbamazepine DDI studies for model evaluation
Open-Systems-Pharmacology/Itraconazole-Digoxin-DDI
Modeling of published clinical Itraconazole-Digoxin-DDI studies for model evaluation
Open-Systems-Pharmacology/Itraconazole-Model
Whole-body PBPK model of itraconazole as CYP3A4 and P-gp DDI perpetrator drug
Open-Systems-Pharmacology/Levonorgestrel
Whole-body PBPK model of levonorgestrel with and without ethinyl estradiol as CYP3A4 DDI victim drug
Open-Systems-Pharmacology/Metformin-Model
Whole-body PBPK model of metformin (OCT2/MATE DDI victim drug)
Open-Systems-Pharmacology/Metoprolol-Model
PBPK model of metoprolol and metoprolol-CYP2D6 drug-gene interactions
Open-Systems-Pharmacology/Midazolam-Model
Whole-body PBPK model of midazolam as CYP3A4 DDI victim drug
Open-Systems-Pharmacology/Ritonavir-Model
PBPK model for ritonavir
Open-Systems-Pharmacology/Theophylline-Model
Whole-body PBPK model of theophylline as CYP1A2 DDI victim drug
Open-Systems-Pharmacology/Verapamil-Model
Verapamil PBPK model